𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Percutaneous absorption of diclofenac in healthy volunteers after single and repeated topical application of diclofenac Emulgel

✍ Scribed by A. Sioufi; F. Pommier; F. Boschet; J. Godbillon; D. Lavoignat; D. Salliere

Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
384 KB
Volume
15
Category
Article
ISSN
0142-2782

No coin nor oath required. For personal study only.

✦ Synopsis

The percutaneous absorption of diclofenac was studied in ten healthy volunteers treated with Emulgel containing 1 -16% diclofenac diethylammonium for 8 d as follows: a single application of 5 g Emulgel on days 1 and 8, and two applications d-I on days 2-7. Plasma concentration profiles of unchanged diclofenac and urinary concentrations of total diclofenac and metabolites (sum of free and conjugated) were determined.

High inter-individual variations in plasma and urine data were recorded, due probably to the permeability and the hydration of the skin. Steady state was reached after 2 d of twice-daily administration. Plasma concentrations were low but remained in the range 10-5Onm0lL-~ over the full day for most of the subjects, indicating prolonged absorption from the application site.

📜 SIMILAR VOLUMES

Percutaneous absorption of [3H]tretinoin
Percutaneous absorption of [3H]tretinoin and systemic exposure to mequinol after dermal application of 2% mequinol/0.01% [3H]tretinoin (Solagé®) solution in healthy volunteers
✍ Donald W. Everett; Thomas J. Franz; Theodore J. Chando; P. Jane Gale; Paul A. Le 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 1 views

Solagé is a combination product composed of 2% mequinol (4-hydroxyanisole) and 0.01% tretinoin (all-trans-retinoic acid) in an ethanolic solution, which is being studied for its safety and efficacy as a topical treatment for disorders of skin hyperpigmentation. The purpose of this study was to evalu

Pharmacokinetics of the angiotensin conv
Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril·HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration
✍ Dr. Günther Kaiser; Roland Ackermann; Sylvia Brechbühler; Walter Dieterle 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 577 KB

The pharmacokinetics of the new angiotensin converting enzyme (ACE) inhibitor benazeprikHC1 were evaluated in healthy male volunteers. The single dose kinetics were established from data of 62 subjects receiving an oral 10 mg dose of the drug. The steady state kinetics were investigated in 15 subjec